Damora Therapeutics (DMRA) Accumulated Expenses (2019 - 2026)

Damora Therapeutics has reported Accumulated Expenses for 8 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 401.0% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (up 401.0% YoY), and the FY2025 full-year result was $2.4 million, up 192.8% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.0 million, up from $2.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $10.5 million in Q1 2023, with the low at $820000.0 in Q4 2024.
• Historically, Accumulated Expenses has averaged $4.6 million across 5 years, with a median of $4.0 million in 2022.
• Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 80.14% — and 2026, when it soared 401.0%.
• Damora Therapeutics' Accumulated Expenses stood at $7.8 million in 2022, then tumbled by 46.78% to $4.1 million in 2023, then sank by 80.14% to $820000.0 in 2024, then soared by 192.8% to $2.4 million in 2025, then jumped by 149.77% to $6.0 million in 2026.
• The last three Accumulated Expenses figures came in at $6.0 million (Q1 2026), $2.4 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.